NCT01819272View on ClinicalTrials.gov

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Met DR

metformin delayed-release tablets

DRUG

Met XR

metformin extended-release tablets

DRUG

Placebo

placebo delayed-release tablets

Sponsors
All Listed Sponsors
lead

Elcelyx Therapeutics, Inc.

INDUSTRY